Male Hypogonadism Therapeutic Pipeline Drugs and Companies Review H1 2015 Research Report Available at RnRMarketResearch.com

Share Article

RnRMarketResearch.com adds “Male Hypogonadism – Pipeline Review, H1 2015” to its store. The report provides an overview of the Male Hypogonadism therapeutic pipeline.

Male Hypogonadism Therapeutic Pipeline

Male Hypogonadism Therapeutic Pipeline

The report “Male Hypogonadism – Pipeline Review, H1 2015” provides comparative analysis on the therapeutic development for Male Hypogonadism. Male hypogonadism is the inability of the testicles to produce testosterone, sperm or both. The symptoms of male hypogonadism includes weakness, muscle and joint aches, increased fat or obesity, enlarged, swollen or tender breasts, reduced facial, body and pubic hair, decreased bone density, bone fractures or osteoporosis, loss of height, sleep apnea, night sweats or hot flushes and fatigue. The report strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Complete report with TOC is available @ http://www.rnrmarketresearch.com/male-hypogonadism-pipeline-review-h1-2015-market-report.html .

The report also reviews key players involved in the therapeutic development for Male Hypogonadism and special features on late-stage and discontinued projects. Companies discussed in this Male Hypogonadism – Pipeline Review, H1 2015 report include AlphaMab Co., Ltd, Antares Pharma, Inc., Auxilium Pharmaceuticals, Inc., Clarus Therapeutics, Inc., Diurnal Ltd
EndoCeutics, Inc., Ferring International Center S.A., Forendo Pharma Oy, Lipocine Inc., M et P Pharma AG, Merck & Co., Inc., Monosol Rx, LLC, Novartis AG, Pantarhei Bioscience BV, Repros Therapeutics Inc. and SoluBest Ltd.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Drug Profiles mentioned in this report are BGS-649, corifollitropin alfa, enclomiphene, fispemifene, follitropin alfa, Kisspeptin-10, Libidua, LPCN-1111, T-2, Testavan, testosterone, testosterone enanthate, testosterone next generation and testosterone undecanoate. Order a purchase copy of this report @ http://www.rnrmarketresearch.com/contacts/purchase?rname=310185 . (This is a premium report priced at US$2000 for a single user License.)

Featured News & Press Releases cover by this report include: Jan 13, 2015: Antares Pharma Announces Update To Quickshot Testosterone Program; Dec 29, 2014: Court Rules Inventors Correctly Named on Androxal Patents; Dec 29, 2014: Repros Updates Androxal Global Regulatory Status; Dec 16, 2014: SOV Therapeutics announces Successful Phase IIb Study of Oral Testosterone Undecanoate for Treatment of Primary and Secondary Hypogonadism in Adult Males; Dec 16, 2014: SOV Therapeutics announces Successful Phase IIb Study of Oral Testosterone Undecanoate for Treatment of Primary and Secondary Hypogonadism in Adult Males; Dec 15, 2014: FDA Confirms Lipocine's Previously-Agreed Clinical Development Plan for LPCN 1021; Nov 25, 2014: Trimel Announces Issuance of Additional Patent Covering NATESTO;
Nov 03, 2014: Antares Pharma Announces Last Patient Enrolled in Phase 3 QuickShot Study Evaluating Testosterone-Deficient Adult Males; Oct 27, 2014: Repros to Webcast Investor and Analyst Day on October 31st; Oct 21, 2014: Results From Long-Term Study of Androxal Exhibit Positive Safety Profile.

List of Tables
Number of Products under Development for Male Hypogonadism, H1 2015 10
Number of Products under Development for Male Hypogonadism - Comparative Analysis, H1 2015 11
Number of Products under Development by Companies, H1 2015 13
Number of Products under Investigation by Universities/Institutes, H1 2015 14
Comparative Analysis by Late Stage Development, H1 2015 15
Comparative Analysis by Clinical Stage Development, H1 2015 16
Comparative Analysis by Early Stage Development, H1 2015 17
Products under Investigation by Universities/Institutes, H1 2015 20
Male Hypogonadism - Pipeline by AlphaMab Co., Ltd, H1 2015 21
Male Hypogonadism - Pipeline by Antares Pharma, Inc., H1 2015 22
Male Hypogonadism - Pipeline by Auxilium Pharmaceuticals, Inc., H1 2015 23
Male Hypogonadism - Pipeline by Clarus Therapeutics, Inc., H1 2015 24
Male Hypogonadism - Pipeline by Diurnal Ltd, H1 2015 25
Male Hypogonadism - Pipeline by EndoCeutics, Inc., H1 2015 26
Male Hypogonadism - Pipeline by Ferring International Center S.A., H1 2015 27
Male Hypogonadism - Pipeline by Forendo Pharma Oy, H1 2015 28
Male Hypogonadism - Pipeline by Lipocine Inc., H1 2015 29
Male Hypogonadism - Pipeline by M et P Pharma AG, H1 2015 30
Male Hypogonadism - Pipeline by Merck & Co., Inc., H1 2015 31
Male Hypogonadism - Pipeline by Monosol Rx, LLC, H1 2015 32
Male Hypogonadism Therapeutics - Recent Pipeline Updates, H1 2015 74
Male Hypogonadism - Dormant Projects, H1 2015 90
Male Hypogonadism - Discontinued Products, H1 2015 91

Explore more reports on Men's Health Therapeutics industry at http://www.rnrmarketresearch.com/reports/life-sciences/pharmaceuticals/therapeutics/mens-health-therapeutics .

About Us:
RnRMarketResearch.com is an online database of market research reports offer in-depth analysis of over 5000 market segments. The library has syndicated reports by leading market research publishers across the globe and also offer customized market research reports for multiple industries.

Share article on social media or email:

View article via:

Pdf Print

Contact Author

Ritesh Tiwari
@RnRMR
since: 06/2012
Follow >
RnR Market Research
Like >
Follow us on
Visit website